Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Any info about Iomega (IOM)? -- Ignore unavailable to you. Want to Upgrade?

To: E. Graphs who wrote (48664)	2/23/1998 9:09:00 PM
From: Rocky Reid	Read Replies (1) \| Respond to of 58324

Re: QGLY Ohhhh.. so that's it! Attack my QGLY will you? I consider this a time to buy as Quigely announced that 1st Q sales could be lower than expected due to the mild Winter here. And it has been, with no snow in the city for 2 years now. But, check out this from the report: biz.yahoo.com Quigley also reported fourth quarter earnings of $0.60 per share versus $0.12 in Q4 1996. Q4 sales of Quigley's cough and cold remedy lozenges jumped more than 600% to $29.2 million from $4.1 million in the year-earlier period. Quigley is now expanding internationally through Merck. QGLY now has a trailing PE of 9. That's right, 9. This leaves a LOT of room to grow, and little downside. The current stock price took a 2 1/2 point hit on the chin today, and at $13 and change is way undervalued. I made a ton on this stock a little over a year ago, and as it grows by 3 figures percentages this year as well, there is a good chance the stock price will certainly beat the S&P, just as it did last year. People have challenged me here to offer a company that is growing more than Iomega. I already have. The name is Quigley.